Abstract 256MO
Background
The multipotent cancer stem-cell differentiates into tumor cell and mesenchymal stromal cell. Depending on the favorability of the tumor microenvironment and the metabolic demand, the ratio of stromal cells to tumor cells differ in the tumor microenvironment. Our study corelates the stromal content in molecular CAF whole body imaging with stroma to tumor ratio and outcomes of locally advanced esophageal cancer patients subjected to different radiation doses with platinum-based doublet chemotherapy regimens.
Methods
54 patients with locally advanced carcinoma of esophagus fitting into definitive chemoradiation therapy protocol were prospectively included in the study after institutional ethical clearance. All patients underwent molecular CAF whole-body imaging prior to initiation of definitive chemoradiation. The SUV Maximum at the primary site were corelated with the stromal content in histopathology. A stromal content of above 50 % was quantified as high stroma. SUV uptake of more than 7 was taken as High SUV. Patients received either 50Gy or 60Gy concurrent with platinum-based doublet chemotherapy. All patients were followed up for a period of minimum 2 years and the response assessment CAF imaging done at the end of 3 months from chemoradiation. The imaging-based response rates, disease free survival and overall survival at the end of 2 years were analyzed.
Results
The local and systemic control of patients with low stromal content is better than that with high stromal content. Amongst the high stromal content, Patients who received 60Gy had better local control rates than the ones that received 50Gy. In the low stromal content irrespective of radiation dose the local control was achieved. The systemic control and overall survival of high stromal content patients appears poorer necessitating the need for further studies on adjuvant, maintenance, or metronomic chemotherapy.
Table: 256MO
Response to chemo-radiotherapy | High stroma (31) | Low stroma (23) |
Complete | 22 (70%) | 21 (91%) |
Partial | 9 (30%) | 2 (9%) |
Radiation dose response to stromal content | ||
50GY(27)-Complete response | 6 (19%) | 11 (47%) |
60GY(27)-Complete response | 16 (51%) | 10 (44%) |
Overall survival at 2 years | 11 | 19 |
Conclusions
CAF Radiological imaging and pathological stromal content quantification could be a Bio-predictive independent tool for radiation dose escalation to augur, telltale responses and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
257MO - Integrating AI and ML with lung cancer diagnostics: A step ahead
Presenter: Shrinidhi Nathany
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
258MO - Discovery of synergistic effect for triple-negative breast cancer immunotherapy using tumor-microenvironment-on-chip
Presenter: Hsuan Yu Mu
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
259MO - A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota
Presenter: Lisa Derosa
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 256MO, 257MO, 258MO and 259MO
Presenter: Christophe Massard
Session: Mini Oral session: Developmental and precision medicine
Resources:
Webcast
Q&A and discussion
Presenter: Christophe Massard
Session: Mini Oral session: Developmental and precision medicine
Resources:
Slides
Webcast
260MO - Liquid biopsy NGS test identifies actionable DNA mutations from CSF specimens of lung cancer patients
Presenter: John Chia
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
261MO - Real-world data on prevalence of MSI-H/dMMR across 6 solid tumor types in Asia
Presenter: David SP Tan
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
262MO - Multi-omics signature for identification of RAS wild-type colorectal cancer liver metastases sensitive to anti-EGFR therapy
Presenter: Wenju Chang
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
263MO - Variant allele frequency and copy number gain in EGFR mutated lung cancer: A menace or a boon?
Presenter: Ullas Batra
Session: Mini Oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 260MO, 261MO, 262MO and 263MO
Presenter: Kaname Nosaki
Session: Mini Oral session: Developmental and precision medicine
Resources:
Slides
Webcast